Acute Myeloid Leukemia The 2 key goals of myeloid growth factor (MGF) use in the management of acute myeloid leukemia (AML) have been (1) a theoretical benefit for “priming” to improve efficacy of chemotherapy, and (2) reduction of neutropenia
Jacqueline N. Poston and Pamela S. Becker
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Featured Updates to the NCCN Guidelines
Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller and Lenora A. Pluchino
filgrastim and pegfilgrastim, are primarily used to reduce the incidence of febrile neutropenia (FN) in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of many chemotherapy regimens. Patients
Johan Maertens, Kristel Buvé and Elias Anaissie
meta-analysis of randomised-controlled trials . Br J Haematol 2005 ; 131 : 22 – 28 . 7. Cornely OA Maertens J Winston DJ . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia . N Engl J Med 2007 ; 356
Gary H. Lyman and Jessica Malone Kleiner
– 454 . 2. Lyman GH Morrison VA Dale DC . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy . Leuk Lymph 2003 ; 44 : 2069 – 2076 . 3. Lyman GH . Guidelines of
Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis and Brahm H. Segal
; 34 : 7 – 14 . 2. Segal BH Almyroudis NG Battiwalla M . Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal
Thanh Ho, Irbaz Bin Riaz, Maheen Akhter, Saad Ullah Malik, Anum Riaz, Muhammad Zain Farooq, Safi U. Khan, Zhen Wang, M. Hassan Murad and Andrea Wahner Hendrickson
.2%–55.8%), vomiting (33.7%, 29.5%–38.3%), neutropenia (24.7%, 15.3%–37.4%), headache (23.9%, 19.9%–28.4%), and reduced appetite (21.7%, 19.3%–24.3%). Myeloid neoplasms were rare (1.2%, 0.7%–1.9%). Incidence of grade 3 or higher AE was 44.3% (30.2%–59.5%) and often
Miguel Quirch, Sriman Swarup, Anita Sultan, Wai L. Thein, Zayar M. Oo, Nyein H. Yu, Myo H. Zaw, Donald P. Quick and Kyaw Z. Thein
.565–1.168; P =.261); neutropenia, 0.956 (95% CI: 0.720–1.268; P =.754); thrombocytopenia, 1.054 (95% CI: 0.450–2.470; P =.904); fatigue, 0.896 (95% CI: 0.761–1.056; P =.192); pyrexia, 1.123 (95% CI: 0.893–1.413; P =.322); and arthralgia, 1.863 (95% CI: 1
Olga Frankfurt and Martin S. Tallman
; 11 : 466 – 478 . 3. Lieschke GJ Grail D Hodgson G . Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization . Blood 1994
Martha Wadleigh and Richard M. Stone
) Group . Leukemia 2007 ; 21 : 453 – 461 . 33 Kern W Aul C Maschmeyer G . Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and
Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Mark B. Geyer, Ivana Gojo, Avyakta Kallam, Wajih Z. Kidwai, Dwight D. Kloth, Eric H. Kraut, Gary H. Lyman, Sudipto Mukherjee, Lia E. Perez, Rachel P. Rosovsky, Vivek Roy, Hope S. Rugo, Sumithira Vasu, Martha Wadleigh, Peter Westervelt and Pamela S. Becker
/HGF_COVID-19.pdf ). 13 We have compiled the following in-depth description of the rationale and evidence supporting our recommendations. Avoidance and Treatment of Neutropenia Febrile neutropenia (FN) is among the most common complications associated with
